載入中
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
前收盤價
US$12.93
−US$0.26 · -1.97%
盤後
US$12.93
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
日內區間
目前US$12.93
52週區間
目前US$12.93
盤中時間採用ET。市場資料可能有所延遲。
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
日內區間
目前US$12.93
52週區間
目前US$12.93
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 3347.8萬 USD | 3937.7萬 USD | 2368.3萬 USD | 1983.4萬 USD | 2298.4萬 USD |
| 銷售、一般及管理費用 | 1585萬 USD | 1214.7萬 USD | 1024萬 USD | 1007.3萬 USD | 949.2萬 USD |
| 營業費用 | 4932.8萬 USD | 5152.4萬 USD | 3392.3萬 USD | 2990.7萬 USD | 3247.6萬 USD |
| 利息收入 | 653.6萬 USD | 360.2萬 USD | 474.8萬 USD | 174萬 USD | 1萬 USD |
| 利息支出 | — | 4000 USD | 39.1萬 USD | 78萬 USD | 120.2萬 USD |
| 折舊和攤銷 | 14.4萬 USD | 14.7萬 USD | 12.3萬 USD | 4.3萬 USD | 5萬 USD |
| 營業利益 | −4932.8萬 USD | −5152.4萬 USD | −3392.3萬 USD | −2990.7萬 USD | −3247.6萬 USD |
| 淨利 | −4275.9萬 USD | −4791.1萬 USD | −2906.5萬 USD | −2915.2萬 USD | −3394萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6739.32萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM3750.91萬0.05%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF2269.39萬0.02%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO1335.67萬0.10%139.17億 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO1022.62萬0.06%180億 USD0.06%US$112.27-0.35%
iShares Biotechnology ETFIBB986.98萬0.09%108.2億 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA833.68萬0.04%218.24億 USD0.03%US$32.66-0.40%
State Street SPDR S&P Pharmaceuticals ETFXPH731.57萬1.58%4.69億 USD0.35%US$64.01-0.99%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAState Street SPDR S&P Pharmaceuticals ETFXPHAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
